Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 2
---
 One American Depositary Share

Up to Pre-Funded Units, Each Pre-Funded Unit Consisting of One Pre-Funded Warrant to Purchase One American Depositary Share

and One Series L Warrant to Purchase One American Depositary Share

Up to American Depositary Shares Representing Ordinary Shares

Up to American Depositary Shares Underlying the Pre-Funded Warrants

Up to American Depositary Shares Representing Ordinary Shares Underlying the Series L Warrants (which contain a “zero exercise price” option)

Up to American Depositary Shares Underlying the Underwriter Warrants

___________________</div>

This preliminary prospectus,
or prospectus, relates to the firm commitment public offering of Units, or Units, of Biodexa Pharmaceuticals PLC, a public limited
company organized under the laws of England and Wales, or the Company, each Unit consisting of (i) one American Depositary Share (representing
10,000 of our ordinary shares, nominal value £0.00005 per share, or Ordinary Shares), or Depositary Shares, and (ii) one Series
L warrant, or Series L Warrant, to purchase one Depositary Share, at an assumed combined public offering price of $ per Unit, based upon
the closing price of our Depositary Shares on the NASDAQ Capital Market on , 2025, or otherwise acquire such greater number of Depositary
Shares as determined in accordance with the provisions of the Series L Warrant upon a “zero exercise price” option (as discussed
below).

Each Series L Warrant will
be immediately exercisable at an exercise price of $ per Depositary Share ( % of the public offering price of each Unit in this offering)
and will expire two and a half (2.5) years after the issuance date. The Series L Warrants also contain certain anti-dilution protections,
certain mechanisms for cashless exercise and contain a “zero exercise price” option, as well as certain reset provisions of
the exercise price and the number of Depositary Shares (represented by Ordinary Shares) underlying the Series L Warrants, as further described
herein.

Under
the “zero exercise price” option of the Series L Warrants, during the period of 90 calendar days following the issue date
of the Series L Warrants, a holder of the Series L Warrant has the right to receive, without payment of any additional cash to the Company,
an aggregate number of Depositary Shares equal to the product of (x) the aggregate number of Depositary